Rabbit Polyclonal Cadherin9 Antibody

+ +

•  

   
     Western blot analysis of Beta-tubulin (acetyl-Lys379) expression in HeLa, NIH3T3, PC12 whole cell lysates.    

•  

   
     Immunofluorescent analysis of Cadherin 9 staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a hidified chamber. Cells were washed with PBST and incubated with Alexa Fluor 647-conjugated secondary antibody (red) in PBS at room temperature in the dark.    

•  

   
     Immunohistochemical analysis of Cadherin 9 staining in human brain formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.    

Cadherin-9 (CDH9) is a calcium-dependent cell adhesion molecule belonging to the cadherin superfamily, which plays critical roles in tissue morphogenesis, synaptic specificity, and neural circuit formation. Predominantly expressed in the central nervous system, CDH9 is implicated in mediating homophilic cell-cell interactions, particularly during brain development. Studies highlight its involvement in axon guidance, neuronal connectivity, and synaptic plasticity, with specific expression patterns observed in regions like the hippocampus and cerebral cortex. Dysregulation of CDH9 has been linked to neurodevelopmental disorders, including autism spectrum disorders (ASD), where genetic variants or altered expression may disrupt neural network assembly.

CDH9 antibodies are essential tools for investigating its expression, localization, and function in both physiological and pathological contexts. These antibodies enable detection of CDH9 in immunoassays (e.g., Western blot, immunohistochemistry) and facilitate studies exploring its role in neural development or disease mechanisms. Recent research also suggests CDH9's potential involvement in cancer progression, particularly in malignancies with neural or epithelial origins, spurring interest in its therapeutic or diagnostic applications. Validation of CDH9 antibodies for specificity and cross-reactivity remains crucial, given the structural homology among cadherin family members. Overall, CDH9 antibodies serve as pivotal reagents for deciphering the molecular basis of neural connectivity disorders and exploring translational opportunities in biomedicine.